Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Horizon Therapeutics Public Limited Company
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the CompanyÔÇÖs research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.

Number of employees : 1 395 people.
Sales per Business
20192020Delta
Orphan929.6071.5%1 787.6681.2% +92.31%
Inflammation370.4328.5%412.7718.8% +11.43%
USD in Million
Sales per region
20192020Delta
United States1 292.4299.4%2 191.1199.6% +69.54%
Rest of World7.610.6%9.320.4% +22.44%
USD in Million
Managers
Name Title Age Since
Timothy Walbert Chairman, President & Chief Executive Officer 53 2010
Paul Hoelscher Chief Financial Officer & Executive Vice President 55 2014
Jeffrey Sherman Chief Medical Officer & Executive Vice President 65 -
Jeffrey Kent Executive VP-Medical Affairs & Outcomes Research 58 2019
Karin Rosen Chief Scientific Officer - 2020
Elizabeth Thompson Executive Vice President-Research & Development - 2018
Barry Moze Chief Administrative Officer & Executive VP 66 2017
Jeff Himawan, Dr. Independent Director 55 2007
William Francis Daniel Independent Director 68 2014
Pascale Witz Independent Director 54 2017
Members of the board
Name Title Age Since
Timothy Walbert Chairman, President & Chief Executive Officer 53 2010
Jeff Himawan, Dr. Independent Director 55 2007
William Francis Daniel Independent Director 68 2014
Pascale Witz Independent Director 54 2017
James Samuel Shannon, Dr. Independent Director 65 2017
H. Thomas Watkins Independent Director 67 2014
Gino Santini Independent Director 64 2012
Susan Mahony, Dr. Independent Director 55 -
Michael G. Grey Director 67 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 227,205,380 222,580,875 98.0% 384,366 0.2% 98.0%
Shareholders
NameEquities%
The Vanguard Group, Inc. 19,536,719 8.65%
Lone Pine Capital LLC 13,997,232 6.20%
Fidelity Management & Research Co. LLC 13,584,629 6.01%
Avoro Capital Advisor LLC 9,000,000 3.98%
Consonance Capital Management LP 6,218,903 2.75%
Paulson & Co., Inc. 6,169,296 2.73%
Janus Capital Management LLC 6,053,732 2.68%
Essex Woodlands Management, Inc. 5,815,940 2.57%
TIAA-CREF Investment Management LLC 5,449,150 2.41%
SSgA Funds Management, Inc. 5,442,017 2.41%
Company contact information
Horizon Therapeutics Plc
Connaught House
1 Burlington Road
1st Floor
Dublin 4

Phone : +353.1.772.2100
Web : http://www.horizontherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Horizon Therapeutics Public Limited Company
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY44.16%23 918
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859
ABBVIE INC.8.18%204 915
MERCK & CO., INC.-9.00%188 031
NOVARTIS AG-11.25%180 565
ASTRAZENECA PLC13.52%171 528
SANOFI9.07%122 030
BRISTOL-MYERS SQUIBB COMPANY-11.41%121 969
AMGEN INC.-13.50%113 104
GLAXOSMITHKLINE PLC14.84%102 790
CHUGAI PHARMACEUTICAL CO., LTD.-33.96%52 902
JIANGSU HENGRUI MEDICINE CO., LTD.-45.63%50 537
BAYER AG-5.78%50 479
DAIICHI SANKYO COMPANY, LIMITED-19.82%48 101
TAKEDA PHARMACEUTICAL COMPANY LIMITED-19.76%41 547
ASTELLAS PHARMA INC.10.10%28 790
CATALENT, INC.22.33%21 794